bioAffinity Technologies (BIAF)

Executive Summary

bioAffinity Technologies is a publicly traded diagnostics company addressing the urgent need for noninvasive, early-stage lung cancer detection. Its lead product, CyPath® Lung, analyzes sputum samples using proprietary flow cytometry and machine learning to accurately identify early-stage lung cancer, the leading cause of cancer-related deaths. The company targets a significant market gap: current screening methods like low-dose CT have low compliance and high false-positive rates, while CyPath Lung offers a simple, low-cost, and highly accurate alternative. As of mid-2026, the company has not yet commercialized its product or received FDA clearance, and its valuation is modest at ~$9.8 million with ~4.5 million shares outstanding. While the technology holds promise, the company faces typical early-stage risks including regulatory hurdles, clinical validation, market adoption, and capital requirements. The path to revenue generation depends on successful FDA approval and subsequent commercialization. However, the strong unmet need and innovative approach position bioAffinity as a potential high-impact player in liquid biopsy diagnostics.

Upcoming Catalysts (preview)

• TBDFDA 510(k) clearance or De Novo authorization for CyPath Lung50% success
• Q3 2026Publication of pivotal clinical trial results in peer-reviewed journal70% success
• TBDStrategic partnership or licensing agreement for distribution40% success